ProtoMed Therapeutics, Inc. is a global oncology-focused biopharmaceutical company. Currently, the company is developing promising pre-clinical and clinical-stage oncology therapeutics. Our mission is to help both patients and physicians through developing innovative and effective medicines.
ProtoMed's is developing discovery and development technologies to unlock high-value drug classes and targets for cancer and additional indications,
ProtoMed's
drug development approach is aimed at identifying, licensing, and acquiring novel clinical-stage assets that target unmet patient needs. At Protomed Therapeutics, we are focused on transforming the treatment of a broad array of malignant and immune-mediated diseases through the development and delivery of promising therapeutics.
ProtoMed Therapeutics is a clinical-stage biotechnology company focused on bringing innovative medicines to patients, both by advancing our internal pipeline of programs and partnering with companies that have novel science or innovative technology.
ProtoMed's
lead asset offers broad therapeutic potential by exploiting mechanisms that play a causal role across a wide array of immune-mediated diseases.
Leveraging the foundational strength of our lead asset, we aim to rapidly enter the clinic and create the proof-of-concept data that will support the advancement of promising therapeutic programs and the development of an expanded pipeline of de-risked drug assets.
ProtoMed is focused on transforming the treatment of a broad array of malignant and immune-mediated diseases through the development and delivery of promising therapeutics.
|
